Payment overview · 2025
General Payments
$772.85
39 reported records · 7 companies
Healthcare provider profile · identity verified
Steven S Salisbury, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOGAN, UT · NPI 1235191495
Verified facts
What the public records show
CMS Open Payments records show Steven S Salisbury, MD received $772.85 in general payments during 2025 across 39 reported records.
Amgen Inc. accounted for 53.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $412.37 | 53.4% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.06 | 17.7% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.28 | 9.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.26 | 8.4% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$48.95 | 6.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.23 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.70 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $772.85 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $221.30 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $166.51 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $166.51 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $137.06 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.28 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.26 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.97 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $48.95 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 245 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 188 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
188 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
245 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 861 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 162 |
| Zolpidem Tartrate | Zolpidem Tartrate | 490 | 66 |
| Omeprazole | Omeprazole | 472 | 133 |
| Metformin Hcl Er | Metformin Hcl | 437 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 398 | 113 |
| Alprazolam | Alprazolam | 320 | 69 |
| Pioglitazone Hcl | Pioglitazone Hcl | 293 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 80 |
| Losartan Potassium | Losartan Potassium | 276 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 259 | 72 |
| Simvastatin | Simvastatin | 251 | 70 |
| Temazepam | Temazepam | 246 | 46 |
| Eliquis | Apixaban | 245 | 49 |
| Potassium Chloride | Potassium Chloride | 245 | 72 |
| Gabapentin | Gabapentin | 237 | 72 |
| Furosemide | Furosemide | 234 | 78 |
| Finasteride | Finasteride | 224 | 58 |
| Celecoxib | Celecoxib | 220 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 211 | 47 |
| Allopurinol | Allopurinol | 208 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 203 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 198 | 66 |
| Carvedilol | Carvedilol | 193 | 52 |
| Mounjaro | Tirzepatide | 188 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 41 |
| Metformin Hcl | Metformin Hcl | 159 | 47 |
| Ezetimibe | Ezetimibe | 153 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 46 |
| Fenofibrate | Fenofibrate | 139 | 43 |
| Lisinopril | Lisinopril | 137 | 42 |
| Tramadol Hcl | Tramadol Hcl | 137 | 40 |
| Lorazepam | Lorazepam | 128 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 127 | 35 |
| Meloxicam | Meloxicam | 124 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 29 |
| Valsartan | Valsartan | 122 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 38 |
| Ozempic | Semaglutide | 110 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 25 |
| Glimepiride | Glimepiride | 106 | 37 |
| Xarelto | Rivaroxaban | 102 | 23 |
| Jardiance | Empagliflozin | 98 | 23 |
| Montelukast Sodium | Montelukast Sodium | 95 | 29 |
| Irbesartan | Irbesartan | 93 | 23 |
| Trazodone Hcl | Trazodone Hcl | 91 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 24 |
| Bupropion Xl | Bupropion Hcl | 84 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 23 |
| Diazepam | Diazepam | 78 | 15 |
| Clonazepam | Clonazepam | 76 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 73 | 20 |
| Pregabalin | Pregabalin | 73 | 14 |
| Famotidine | Famotidine | 70 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 24 |
| Buspirone Hcl | Buspirone Hcl | 66 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 23 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 61 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 20 |
| Estradiol | Estradiol | 58 | 17 |
| Prednisone | Prednisone | 57 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 16 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Digoxin | Digoxin | 45 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 12 |
| Fluconazole | Fluconazole | 41 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 11 |
| Ondansetron Odt | Ondansetron | 37 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 13 |
| Ibuprofen | Ibuprofen | 36 | 20 |
| Levofloxacin | Levofloxacin | 36 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | 13 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 23 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 14 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Zolmitriptan | Zolmitriptan | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $772.85 · 39 records | Amgen Inc. | ELIQUIS, EVENITY, JARDIANCE, KRYSTEXXA, Kerendia, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, PROLIA, REPATHA, VRAYLAR, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error